CERC's Woes Continue, TXMD Replenished By Trial Data, NDRM Abuzz, SRNE On Watch

Shares of Cerecor Inc. (CERC) plunged over 13% on Monday on disappointing top-line clinical results from its phase II clinical trial of CERC-501 for smoking cessation.

from RTT - Biotech http://ift.tt/2gXo0RY
via IFTTT